<DOC>
	<DOCNO>NCT02171728</DOCNO>
	<brief_summary>Investigation maximum tolerate dose ( MTD ) , safety , pharmacokinetics , pharmacodynamic parameter , efficacy BIBW 2992</brief_summary>
	<brief_title>Dose Escalation Study Continuous Once-daily Oral Treatment With BIBW 2992 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female patient confirm diagnosis advance , nonresectable and/or metastatic solid tumor , type historically know express EGFR and/or HER2 ( Human Epidermal Growth Factor Receptor ) , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment preferably patient breast , colorectal prostate cancer Age 18 year old Life expectancy least three ( 3 ) month Written inform consent consistent International Conference Harmonization Good Clinical Practice guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 2 Patients recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy CTC &lt; =Grade 1 Patients must recover previous surgery The 12 additional patient recruit MTD must also meet follow criterion : Measurable tumor deposit ( RECIST ) one technique ( Xray , CT , MRI ) and/or recognize tumor marker prostatespecific antigen ( PSA ) ( prostate cancer ) cancer antigen ( CA ) 125 ( ovarian cancer ) Active infectious disease Gastrointestinal disorder may interfere absorption study drug chronic diarrhea Serious illness concomitant nononcological disease consider investigator incompatible protocol Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least eight ( 8 ) week , history cerebral edema bleed past eight ( 8 ) week requirement steroid antiepileptic therapy Cardiac leave ventricular function rest ejection fraction CTC &gt; =Grade 1 Absolute neutrophil count ( ANC ) less 1500/mm3 Platelet count less 100 000/mm3 Bilirubin great 1.5 mg /dl ( &gt; 26 μmol /L , SI unit equivalent ) Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg/dl ( &gt; 132 μmol/L , Système Internationale unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breastfeed Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( exclude Luteinizing HormoneReleasing Hormone ( LHRH ) agonists , hormone take breast cancer , bisphosphonates ) , participation another clinical study within past four week start therapy concomitantly study Treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly study ( eight week trastuzumab ) Patients unable comply protocol Active alcohol drug abuse A patient may eligible retreatment previous course finish . A patient eligible follow condition meet : Patients clinical sign disease progression late Xray , CT MRI reveal disease progression Cardiac leave ventricular function CTC Grade ≥ 2 time previous course Patients fulfil Exclusion Criteria ( except criterion 5 ) list determine On Day 28 treatment period 1 Visit R1 current course patient enter repeat treatment period ( treatment period 2 ) , On Visit R5 previous course Visit R1/C1 current course patient repeat treatment period ( treatment course 3 6 ) enter continuous treatment period ( treatment course 7 ) , On Visit C3 previous course Visit C1 current course patient continuous treatment period ( treatment course 8 final discontinuation ) Patient recover doselimiting toxicity ( DLT ) 14 day last administration BIBW 2992 previous course . Recovery define return baseline level CTC Grade 1 , whichever high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>